Enforced expression of Shisa3 in TAMs enables cancer immunotherapy by NF‐κB‐mediated reprogramming of TAMs toward an antitumoral phenotype, thus enhances the efficacy of immune checkpoint blockade (ICB) therapy. The gene discussed is SHISA3; the disease is cancer.